| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.2217/14750708.5.6.759 |
| P698 | PubMed publication ID | 18188561 |
| P2093 | author name string | E A Repasky | |
| S H Beachy | |||
| P2860 | cites work | How to measure renal function in clinical practice | Q24672086 |
| Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies | Q28036762 | ||
| Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group | Q28141498 | ||
| Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial | Q44945181 | ||
| Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis | Q45093115 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Increase in carotid intima-media thickness in grade I hypertensive subjects: white-coat versus sustained hypertension | Q46672448 | ||
| Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis | Q46730817 | ||
| Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials | Q47442278 | ||
| Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. | Q50934595 | ||
| New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. | Q51929570 | ||
| Blood-pressure screening and supervision in general practice | Q55642743 | ||
| 2007 Guidelines for the Management of Arterial Hypertension | Q56970780 | ||
| Commentary: Controversies in NICE guidance on chronic kidney disease | Q57496366 | ||
| Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group | Q28328155 | ||
| Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Q29618529 | ||
| Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group | Q29619460 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Atenolol in hypertension: is it a wise choice? | Q33208768 | ||
| Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis | Q33226226 | ||
| Toxicity of mercury | Q33749488 | ||
| Abandoning diastole | Q33796536 | ||
| Impact of high-normal blood pressure on the risk of cardiovascular disease | Q34109606 | ||
| A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. | Q34176994 | ||
| Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra | Q34189543 | ||
| Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. | Q34299778 | ||
| Calcium antagonist-induced gingival hyperplasia | Q34337716 | ||
| Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association | Q34338939 | ||
| White-coat hypertension as a cause of cardiovascular dysfunction | Q34394804 | ||
| Pattern of declining blood pressure across replicate population surveys of the WHO MONICA project, mid-1980s to mid-1990s, and the role of medication. | Q34452559 | ||
| Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 | ||
| Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial | Q34683498 | ||
| Treatment of hypertension in patients 80 years of age or older | Q34766135 | ||
| Global burden of blood-pressure-related disease, 2001. | Q34775810 | ||
| Formula estimation of glomerular filtration rate: have we gone wrong? | Q35838869 | ||
| Angioedema due to ACE inhibitors: increased risk in patients of African origin | Q36053645 | ||
| Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension | Q36088984 | ||
| Pharmacological management of hypertension. | Q37056533 | ||
| Systolic pressure is all that matters | Q37194051 | ||
| Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study | Q37368689 | ||
| Improvement of medication compliance in uncontrolled hypertension | Q39467140 | ||
| Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker | Q40215477 | ||
| Major clinical trials of hypertension: what should be done next? | Q40420427 | ||
| Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 | ||
| Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study | Q40804261 | ||
| Low-dose spironolactone in the management of resistant hypertension: a surveillance study | Q42614218 | ||
| Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. | Q43576144 | ||
| Cardiovascular protection and blood pressure reduction: a meta-analysis | Q43782892 | ||
| An assessment of the sources of dietary salt in a British population | Q43900850 | ||
| Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients | Q44087052 | ||
| Estimating the proportion of young adults on antihypertensive treatment that have been correctly diagnosed | Q44312338 | ||
| Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine | Q44417540 | ||
| Diarrhoea, vomiting and ACE inhibitors:--an important cause of acute renal failure | Q44452202 | ||
| P433 | issue | 6 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 759-775 | |
| P577 | publication date | 2008-01-10 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update | |
| P478 | volume | 57 |
| Q46339965 | A novel role of serum cytochrome c as a tumor marker in patients with operable cancer |
| Q24648447 | A strategy for blood biomarker amplification and localization using ultrasound |
| Q37919589 | Biomarkers in T cell therapy clinical trials |
| Q36177752 | Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients |
| Q84511640 | Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients |
| Q45796080 | Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy |
| Q33694691 | Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling |
| Q34754071 | Identification and validation of SRC and phospho-SRC family proteins in circulating mononuclear cells as novel biomarkers for pancreatic cancer |
| Q44844478 | Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy |
| Q33913086 | Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients |
| Q36893247 | Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay. |
| Q37184228 | Silicon micro- and nanofabrication for medicine |
| Q35222365 | The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy. |
Search more.